Paclitaxel and Spirulina Nanoparticle for Cancer Therapy: Effect of Spirulina on Oral Bioavailability of Paclitaxel
$ 32.5
Description
Paclitaxel and spirulina when administered as nanoparticles, found to be very much potential against cancer. Paclitaxel and Spirulina nanoparticle was formulated using precipitation technique and optimized with Central Composite Rotatable Design (CCRD) using Response Surface Methodology (RSM). The optimal formulation of polymer concentration 48 mg, surfactant concentration 45% and stirring time of 60 min gave rise to an Entrapment Efficiency (EE) of 98.12 ± 1.3 %, Drug Loading of 15.61 ± 1.9 %, mean diameter of 198 ± 4.7 nm and zeta potential of -25mV. The surface morphology of the optimized nanoparticle determined using Scanning Electron Microscopy (SEM) was shperical in shape. The release of paclitaxel and spirulina from the nanoparticle matrix at pH 6.2 was almost 45% and 80% in the first 5 h and 120 h, respectively. The oral bioavailability for the paclitaxel spirulina nanoparticles developed is 24.0% at 10 mg/kg paclitaxel dose, which is 10 fold higher that that of oral pure paclitaxel. There was an increase in overall survival in an MKN45-transplanted mice model and notable improvement in anti-tumour efficacy when Paclitaxel-Spirulina nanoparticle was delivered through intra-tumoral administration. The conjecture of this research is that, the Paclitaxel-Spirulina nanoparticles could be an effective chemotherapeutic formulation for cancer.